PUNE, India, November 4, 2016 /PRNewswire/ -- RnRMarketResearch.com adds "Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape" to its store, stating that although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium and Remicade, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth. The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%. Complete report on Gastrointestinal Drug Market with 23 market data tables and 71 figures, spread across 161 pages is available at http://www.rnrmarketresearch.com/global-gastrointestinal-drug-market-to-2022-pipeline-characterized-by-emerging-biologic-therapies-while-tnf-inhibitors-and-ppis-continue-to-dominate-therapy-landscape-market-report.html . Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010). Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development. Companies Analysis and Positioning discussed in this research are AbbVie, Takeda, Johnson & Johnson, AstraZeneca, Alexion, Allergan and Celgene.